COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
16 hedge funds and large institutions have $1.3M invested in COSCIENS Biopharma Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
215% more call options, than puts
Call options by funds: $482K | Put options by funds: $153K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 15 → 16 (+1)
0.05% less ownership
Funds ownership: 0.08% → 0.03% (-0.05%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
63% less capital invested
Capital invested by funds: $3.48M → $1.3M (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$150K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$21.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$9.12K |
| 4 |
Morgan Stanley
New York
|
+$8.24K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
+$2.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.18M |
| 2 |
Renaissance Technologies
New York
|
-$278K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$275K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$118K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$22.7K |
CSCI Hedge Fund Activity: Q1 2017 in Review
16 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q1 2017, worth a combined $1.3M — down 63% from $3.48M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CSCI positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $150K. The largest seller was Sabby Management, exiting entirely with an estimated $1.18M sold.
- 16 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q1 2017, up from 15 in Q4 2016.
- Funds reported $1.3M of COSCIENS Biopharma Inc. Common Stock stock for Q1 2017, down 63% quarter-over-quarter.
- 5 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q1 2017 and 4 closed out, a net change of +1 holder.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q1 2017 was Susquehanna International Group, an estimated $150K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q1 2017 was Sabby Management, an estimated $1.18M sold.
Based on aggregated 13F filings for Q1 2017.